Trius Therapeutics Inc Revenue Growth Rates (TSRX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Trius Therapeutics Inc  (TSRX)
 

TSRX's Revenue Growth by Quarter and Year

Trius Therapeutics Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TSRX Revenue (in millions $) FY 2013 FY 2012 FY 2011 FY 2010
4th Quarter December -
3rd Quarter September -
2nd Quarter June 1.29
1st Quarter March 1.73
FY 3.02





TSRX Revenue second quarter 2013 Y/Y Growth Comment
Trius Therapeutics Inc reported drop in Revenue in the second quarter 2013 by -79.24% to $ 1.29 millions, from the same quarter in 2012.
The fall in the second quarter 2013 Trius Therapeutics Inc's Revenue compares unfavorably to the Company's average Revenue jump of 48.23%.

According to the results reported in the second quarter 2013, Trius Therapeutics Inc achieved the best Revenue growth in Biotechnology & Pharmaceuticals industry. While Trius Therapeutics Inc' s Revenue meltdown of -79.24% ranks overall at the positon no. 17 in the second quarter 2013.


TSRX Revenue ( Y/Y Growth %) 2013
 2012 2011 2010
4th Quarter December - 3.2 % 157.73 % -
3rd Quarter September - -80.39 % 1363.46 % -
2nd Quarter June -79.24 % 117.48 % - -
1st Quarter March -82.4 % 261.4 % - -
FY   - -33.74 % 920.4 % -

Financial Statements
Trius Therapeutics Inc's second quarter 2013 Revenue $ 1.29 millions TSRX's Income Statement
Trius Therapeutics Inc's second quarter 2012 Revenue $ 6.22 millions Quarterly TSRX's Income Statement


TSRX Revenue (Quarter on Quarter Growth %)

 2013
 2012 2011 2010
4th Quarter December - -13.57 % -83.57 % -6.73 %
3rd Quarter September - -4.02 % 964.34 % -
2nd Quarter June -25.38 % -36.72 % 5.15 % -
1st Quarter March -66.47 % 96.6 % 40.21 % -
FY (Year on Year)   - -33.74 % 920.4 % -


Back to TSRX Growth rate Comparisons >> Back to TSRX Growth rate Comparisons >>


Revenue second quarter 2013 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #1
Healthcare Sector #5
Overall #17

Revenue Y/Y Growth Statistics
High Average Low
436.5 % 48.23 % -72.53 %
(Jun 30 2012)   (Jun 30 2013)
Revenue second quarter 2013 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #1
Healthcare Sector #5
Overall #17
Revenue Y/Y Growth Statistics
High Average Low
436.5 % 48.23 % -72.53 %
(Jun 30 2012)   (Jun 30 2013)

Revenue by Quarter for the Fiscal Years 2010, 2011, 2012, 2013

Trius Therapeutics Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
964.57 % 82.98 % -83.57 %
(Sep 30 2011)  


TSRX's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2013 Trius Therapeutics Inc disclosed fall in Revenue from the first quarter by -25.38% to $ 1.29 millions, from $ 1.73 millions achived in the previous reporting period.

But that's not important problem, as Trius Therapeutics Inc's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 46 other companies have achieved higher Revenue quarter on quarter growth. While Trius Therapeutics Inc's Revenue growth quarter on quarter, overall rank is 3653.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #47
Healthcare Sector #426
Overall #3653
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #47
Healthcare Sector #426
Overall #3653
Revenue Q/Q Growth Statistics
High Average Low
964.57 % 82.98 % -83.57 %
(Sep 30 2011)  


TSRX's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2013 Trius Therapeutics Inc disclosed fall in Revenue from the first quarter by -25.38% to $ 1.29 millions, from $ 1.73 millions achived in the previous reporting period.

But that's not important problem, as Trius Therapeutics Inc's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 46 other companies have achieved higher Revenue quarter on quarter growth. While Trius Therapeutics Inc's Revenue growth quarter on quarter, overall rank is 3653.


Trius Therapeutics Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2013)		 12 Months Ending
(Mar 31 2013)		 12 Months Ending
(Dec 31 2012)		 12 Months Ending
(Sep 30 2012)		 12 Months Ending
(Jun 30 2012)
Cumulative Revenue 12 Months Ending $ 14.15 $ 19.08 $ 27.19 $ 27.03 $ 51.49
Y / Y Revenue Growth (TTM) -72.53 % -60.36 % -33.71 % -28.77 % 436.5 %
Year on Year Revenue Growth Overall Ranking # 17 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) -25.85 % -29.81 % 0.57 % -47.51 % 6.99 %
Seq. Revenue Growth (TTM) Overall Ranking # 630 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
Trius Therapeutics Inc's cumulative 12 months Revenue continue to drop, but on the faster rate at -72.53% year on year, at Jun 30 2013 compare to the -60.36% decrease at Mar 31 2013. If the Trius Therapeutics Inc's fiscal year would end at Jun 30 2013, annual Revenue would be $14 millions.

Among companies within the Healthcare sector 4 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 17.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 8
Healthcare Sector # 5
Overall # 17

Revenue TTM Y/Y Growth Statistics
High Average Low
436.5 %
 48.23 %
-72.53 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 57
S&P 500 # 630
Cumulative Revenue growth Comment
Trius Therapeutics Inc's cumulative 12 months Revenue continue to drop, but on the faster rate at -72.53% year on year, at Jun 30 2013 compare to the -60.36% decrease at Mar 31 2013. If the Trius Therapeutics Inc's fiscal year would end at Jun 30 2013, annual Revenue would be $14 millions.

Among companies within the Healthcare sector 4 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 17.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 8
Healthcare Sector # 5
Overall # 17

Revenue TTM Y/Y Growth Statistics
High Average Low
436.5 %
48.23 %
-72.53 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 57
S&P 500 # 630




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
TSRX's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2013 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2013
Waters Corporation-0.08%$ -0.078 millions
Cutera Inc -0.16%$ -0.158 millions
Utah Medical Products Inc-0.23%$ -0.229 millions
Dentsply Sirona Inc -0.26%$ -0.260 millions
Agios Pharmaceuticals Inc -0.32%$ -0.318 millions
St Jude Medical Inc-0.50%$ -0.496 millions
Vanda Pharmaceuticals Inc -0.70%$ -0.704 millions
Msa Safety Inc-0.91%$ -0.909 millions
Boston Scientific Corporation-1.04%$ -1.039 millions
Progenics Pharmaceuticals Inc-1.04%$ -1.044 millions
Teva Pharmaceutical Industries Limited-1.40%$ -1.402 millions
Gadsden Properties, Inc.-1.43%$ -1.428 millions
Ds Healthcare Group, Inc.-1.92%$ -1.918 millions
Micron Solutions Inc-1.94%$ -1.940 millions
Milestone Scientific Inc -2.09%$ -2.095 millions
Integra Lifesciences Holdings Corp-2.20%$ -2.200 millions
Prestige Consumer Healthcare Inc -2.74%$ -2.739 millions
Procyon Corporation-2.74%$ -2.744 millions
Cas Medical Systems Inc-3.00%$ -2.999 millions
Epizyme Inc.-3.28%$ -3.279 millions
American Bio Medica Corporation-3.33%$ -3.331 millions
Quidelortho Corp-3.73%$ -3.733 millions
Sunlink Health Systems Inc -4.46%$ -4.461 millions
Stablecoin Development Corporation-4.59%$ -4.592 millions
Tivity Health Inc -4.67%$ -4.667 millions
Quest Diagnostics Inc-4.78%$ -4.776 millions
Allied Healthcare Products inc -5.01%$ -5.006 millions
Dynatronics Corporation-6.13%$ -6.135 millions
Gentium S.p.a.-6.33%$ -6.330 millions
Rti Surgical Holdings Inc -6.39%$ -6.390 millions


About Trius Therapeutics Inc Revenue Growth Rates (TSRX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.